Dewei She

4.0k total citations
44 papers, 2.4k citations indexed

About

Dewei She is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Dewei She has authored 44 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Physiology, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Dewei She's work include Asthma and respiratory diseases (13 papers), Multiple Sclerosis Research Studies (9 papers) and Peripheral Neuropathies and Disorders (7 papers). Dewei She is often cited by papers focused on Asthma and respiratory diseases (13 papers), Multiple Sclerosis Research Studies (9 papers) and Peripheral Neuropathies and Disorders (7 papers). Dewei She collaborates with scholars based in United States, Germany and France. Dewei She's co-authors include Judith K. Jones, Suellen M. Curkendall, Earl Goehring, Stephan Lanes, Mary Rose Stang, Christopher E. Brightling, Edward Piper, René van der Merwe, Richard May and William A. Rees and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Neurology.

In The Last Decade

Dewei She

42 papers receiving 2.3k citations

Peers

Countries citing papers authored by Dewei She

Since Specialization

Citations

This map shows the geographic impact of Dewei She's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dewei She with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dewei She more than expected).

Fields of papers citing papers by Dewei She

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dewei She. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dewei She. The network helps show where Dewei She may publish in the future.

Co-authorship network of co-authors of Dewei She

This figure shows the co-authorship network connecting the top 25 collaborators of Dewei She. A scholar is included among the top collaborators of Dewei She based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dewei She. Dewei She is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial 2024 ·The Lancet Neurology ·Bruce Cree, Ho Jin Kim, Brian G. Weinshenker, Sean J. Pittock, Dean M. Wingerchuk, Kazuo Fujihara, Friedemann Paul, Gary Cutter, Romain Marignier, Ari Green, Orhan Aktaş, Hans‐Peter Hartung, Dewei She, William A. Rees, (unknown), Daniel Cimbora, Eliezer Katz, Jeffrey L. Bennett	20
2	Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder 2023 ·Journal of Neurology Neurosurgery & Psychiatry ·Orhan Aktaş, Hans‐Peter Hartung, (unknown), William A. Rees, Kazuo Fujihara, Friedemann Paul, Romain Marignier, Jeffrey L. Bennett, Ho Jin Kim, Brian G. Weinshenker, Sean J. Pittock, Dean M. Wingerchuk, Gary Cutter, Dewei She, Michele Gunsior, Daniel Cimbora, Eliezer Katz, Bruce Cree	20
3	Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism 2023 ·Annals of Clinical and Translational Neurology ·Ho Jin Kim, Orhan Aktaş, Kristina R. Patterson, (unknown), Amy Kunchok, Jeffrey L. Bennett, Brian G. Weinshenker, Friedemann Paul, Hans‐Peter Hartung, Daniel Cimbora, (unknown), Nanette Mittereder, William A. Rees, Dewei She, Bruce Cree	8
4	Evaluation Of Infusion Reactions And Infusion Times In The N-Momentum Study Of Inebilizumab For NMOSD (1941) 2021 ·Neurology ·Mark Tullman, (unknown), Dewei She, Eliezer Katz, Bruce Cree	2
5	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder 2021 ·Multiple Sclerosis and Related Disorders ·Romain Marignier, Sean J Pittock, Friedemann Paul, Ho Jin Kim, Jeffrey L. Bennett, Brian G. Weinshenker, Dean M. Wingerchuk, Ari Green, Kazuo Fujihara, Gary Cutter, Orhan Aktaş, Hans‐Peter Hartung, Jörn Drappa, John N. Ratchford, Dewei She, (unknown), William A. Rees, Daniel Cimbora, Eliezer Katz, Bruce Cree	24
6	Long Term Safety Outcomes with Inebilizumab Treatment in NMOSD: the N-MOmentum Trial (2283) 2021 ·Neurology ·Bruce Cree, Jeffrey L. Bennett, Brian G. Weinshenker, Dean M. Wingerchuk, Friedemann Paul, Ho Jin Kim, Sean J. Pittock, Kazuo Fujihara, Gary Cutter, Romain Marignier, Orhan Aktaş, Hans‐Peter Hartung, Ari Green, Jörn Drappa, Dewei She, Daniel Cimbora, William A. Rees, John N. Ratchford, Eliezer Katz	2
7	A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adult Subjects with Neuromyelitis Optica Spectrum Disorders–Top line efficacy and safety results (Plen02.001) 2019 ·Neurology ·Bruce Cree, Jeffrey L. Bennett, Ho Jin Kim, Brian Weinshenker, Sean J. Pittock, Dean M. Wingerchuk, Kazuo Fujihara, Friedemann Paul, Gary Cutter, Romain Marignier, Ari Green, Orhan Aktaş, Hans‐Peter Hartung, Jörn Drappa, Gerard Barron, (unknown), (unknown), Dewei She, Eliezer Katz	4
8	Abstract 14664: Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Recombinant Human Lecithin-Cholesterol Acyltransferase (MEDI6012) in Subjects With Stable Coronary Heart Disease 2017 ·Circulation ·Richard T. De George, (unknown), (unknown), Dewei She, Nicholas Buss, Rebecca Bakker‐Arkema, Michael J. Koren, Boaz Hirshberg	1
9	A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis 2017 ·American Journal of Respiratory and Critical Care Medicine ·Joseph M. Parker, Ian Glaspole, Lisa Lancaster, Tarik Haddad, Dewei She, Stephanie L. Roseti, (unknown), Ethan Grant, Chris Kell, Kevin R. Flaherty	90
10	Effect of Anti–IL-13 Treatment on Airway Dimensions in Severe Asthma 2016 ·American Journal of Respiratory and Critical Care Medicine ·Christopher E. Brightling, Lars H. Nordenmark, Meena Jain, Edward Piper, Dewei She, Martin Braddock, Gene Colice, Göran Tornling	10
11	Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial 2015 ·The Lancet Respiratory Medicine ·Christopher E. Brightling, Pascal Chanez, Richard Leigh, Paul M. O’Byrne, Stephanie Korn, Dewei She, Richard May, Katie Streicher, Koustubh Ranade, Edward Piper	285
12	Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study 2014 ·The Lancet Respiratory Medicine ·Christopher E. Brightling, Eugene R. Bleecker, Reynold A. Panettieri, Mona Bafadhel, Dewei She, Christine K. Ward, Xiao Xu, Claire Birrell, René van der Merwe	225
13	A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma 2012 ·European Respiratory Journal ·Edward Piper, Christopher E. Brightling, Robert Niven, Chad K. Oh, Raffaella Faggioni, (unknown), Dewei She, Chris Kell, Richard May, Gregory P. Geba, Néstor A. Molfino	290
14	Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma 2011 ·European Respiratory Journal ·Edward Piper, Christopher E. Brightling, Robert Niven, Chad K. Oh, Raffaella Faggioni, (unknown), Dewei She, Chris Kell, Richard May, Gregory P. Geba, Néstor A. Molfino	7
15	Trend tests for genetic association using population-based cross-sectional complex survey data 2009 ·Biostatistics ·Dewei She, Yan Li, Han Zhang, B. I. Graubard, (unknown)	1
16	Testing Hardy‐Weinberg Equilibrium using Family Data from Complex Surveys 2009 ·Annals of Human Genetics ·Dewei She, Hong Zhang, Zhaohai Li	4
17	Chronic obstructive pulmonary disease severity and cardiovascular outcomes 2006 ·European Journal of Epidemiology ·Suellen M. Curkendall, Stephan Lanes, Cynthia de Luise, Mary Rose Stang, Judith K. Jones, Dewei She, Earl Goehring	90
18	Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations 2006 ·Clinical Infectious Diseases ·Robert L. Atmar, W Keitel, Shital M. Patel, (unknown), Dewei She, Hana M. El Sahly, Justine Pompey, T. R. Cate, R. B. Couch	116
19	Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Saskatchewan Canada 2005 ·Annals of Epidemiology ·Suellen M. Curkendall, (unknown), Judith K. Jones, Stephan Lanes, Mary Rose Stang, Earl Goehring, Dewei She	488
20	Impact of cisapride label changes on codispensing of contraindicated medications 2003 ·Pharmacoepidemiology and Drug Safety ·Jeff J. Guo, Suellen M. Curkendall, Judith K. Jones, Daniel Fife, Earl Goehring, Dewei She	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact